Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Zealands nye opkøb

Planlagt Fastgjort Låst Flyttet Debatforum
0 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Stockwatch1
    wrote on sidst redigeret af
    #1

    Zealand Pharma meldte i går ganske overraskende om et opkøb, hvormed selskabet forstærker sin peptid-platform markant. De bruger dog også af deres kassebeholdning, hvilket øger risikoen for en emissionen senere hen.

    Der er ikke mange banker, der har kommenteret købet. Jeg har modtaget dette fra Bryan Garnier i dag:

    • Zealand yesterday announced the opportunistic acquisition of assets consisting mainly of patents and a library of peptides from Encycle Therapeutics at no cost, at least until the lead asset successfully completes phase II trials. So far ET3764, an orally-delivered integrin alpha4-beta7 inhibitor, is at the PC stage and requires some more work in higher species before it can go for an IND. It is the first time Zealand acquires an external asset which has to be seen as a strong sign of commitment to its leadership position in the field of peptides. Having the broadest possible library of compounds to test before picking up the next possible candidate to go in the clinics is key to the new CEO.

    • Clearly it is much too early to think about what can come out of this acquisition even though the target of the first asset has been validated already by Entyvio in ulcerative colitis and Crohn's disease i.e. two diseases in the GI field where Zealand wants to build around glepaglutide (SBS). And the oral route might represent some kind of advantage. But the CEO acknowledged that UC was very busy and would require significant investments to go commercial, hence the open game to decide later on where to go and under which overall scheme, considering that a mix of large indications in partnership or licensing-out and smaller ones in stand-alone is a possible way forward.

    1 Reply Last reply
    6

    Hello! It looks like you're interested in this conversation, but you don't have an account yet.

    Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

    With your input, this post could be even better 💗

    Tilmeld Log ind

    • Log ind

    • Har du ikke en konto? Tilmeld

    • Login or register to search.
    • First post
      Last post
    0
    • Debatforum
    • Seneste
    • Populære
    • Bruger